Immunotherapy plus chemotherapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that is advanced or has spread and cannot be surgically removed.
- You are 18 years or older.
- You are in good enough physical condition to be up and about (ECOG score 0 or 1).
- If you had chemotherapy or radiation before surgery, at least 6 months have passed before the cancer came back.
- You have at least one measurable or evaluable tumor lesion.
- You can provide a tissue sample (biopsy) for PD-L1 testing.
- Your blood counts, liver, and kidney function meet certain levels.
- You have not had prior systemic treatment for advanced or metastatic disease.
- You are not allergic to the study drugs or have certain medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiotherapy can help people aged 75 or older with locally advanced stomach cancer. It aims to shrink tumors and improve outcomes.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a combination of two drugs (liposomal irinotecan and sintilimab) for people with stomach or gastroesophageal junction cancer that has progressed after at least one round of standard chemotherapy. The goal is to see if this combo can help shrink tumors or slow the cancer's growth.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
This trial tests combining an immunotherapy drug (sintilimab) with a targeted therapy (ramucirumab) and chemotherapy (paclitaxel) for stomach cancer that came back soon after surgery and chemotherapy. The goal is to see if this combined approach can help control the cancer and prolong life.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.